{"id":"placebo-tablet-bid","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL211543","moleculeType":"Small molecule","molecularWeight":"497.60"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo tablets are inactive formulations designed to match the appearance and administration schedule of an active drug. They serve as the control arm in randomized controlled trials to measure the effect of the investigational drug against baseline and psychological expectation effects. Any observed benefit in the placebo group is attributed to natural disease progression, regression to the mean, or the placebo effect itself.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:32.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trial (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06964776","phase":"PHASE1","title":"A Study of LY4268989 (MORF-057) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-05-01","conditions":"Healthy","enrollment":144},{"nctId":"NCT04734080","phase":"PHASE4","title":"Dronabinol in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-03-09","conditions":"Total Knee Arthroplasty, Opioid Use","enrollment":114},{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT06679140","phase":"PHASE3","title":"A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-12-08","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":2330},{"nctId":"NCT04026997","phase":"PHASE2","title":"A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis","status":"TERMINATED","sponsor":"CinDome Pharma, Inc.","startDate":"2019-09-11","conditions":"Gastroparesis","enrollment":72},{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":606},{"nctId":"NCT03617679","phase":"PHASE2","title":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-03-06","conditions":"Metastatic Endometrial Cancer","enrollment":79},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT04781543","phase":"PHASE2","title":"A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-11-05","conditions":"Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic","enrollment":301},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT07339631","phase":"PHASE1","title":"Sodium Aescinate for the Treatment of Low Back Pain (LBP) in Adults","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-01","conditions":"Low Back Pain, Paraspinal Muscle, CLBP - Chronic Low Back Pain","enrollment":40},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT05618353","phase":"PHASE4","title":"The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-08-21","conditions":"Coronary Artery Disease","enrollment":700},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT05940493","phase":"PHASE2","title":"Abemaciclib in Newly Diagnosed Meningioma Patients","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2025-03-24","conditions":"Meningioma","enrollment":72},{"nctId":"NCT06345404","phase":"PHASE1","title":"Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD","status":"COMPLETED","sponsor":"Corvus Pharmaceuticals, Inc.","startDate":"2024-04-16","conditions":"Atopic Dermatitis","enrollment":82},{"nctId":"NCT03561584","phase":"PHASE2","title":"Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-07-01","conditions":"Primary Sclerosing Cholangitis","enrollment":32},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":"HIV/AIDS, Heart Failure With Preserved Ejection Fraction","enrollment":39},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT05658575","phase":"PHASE2, PHASE3","title":"Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","status":"RECRUITING","sponsor":"Olatec Therapeutics LLC","startDate":"2023-01-06","conditions":"Acute Gout Flare, Gout Attack, Gout Flare","enrollment":300},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05040321","phase":"PHASE1, PHASE2","title":"Sirtuin-NAD Activator in Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-12-01","conditions":"Alzheimer's Disease (Incl Subtypes), Dementia","enrollment":22},{"nctId":"NCT05633810","phase":"PHASE3","title":"COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2022-12-21","conditions":"Diabete Type 2, Cardiovascular Diseases","enrollment":10000},{"nctId":"NCT06414954","phase":"PHASE2","title":"Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis","status":"RECRUITING","sponsor":"NMD Pharma A/S","startDate":"2024-05-16","conditions":"Myasthenia Gravis, Myasthenia Gravis, MuSK","enrollment":84},{"nctId":"NCT07458061","phase":"PHASE1, PHASE2","title":"Kamuvudine-9 (K9) in Diabetic Macular Edema","status":"RECRUITING","sponsor":"Dr. Bryan Strelow","startDate":"2026-02","conditions":"Diabetic Macular Edema","enrollment":10},{"nctId":"NCT05296837","phase":"PHASE4","title":"Ocular Rosacea Biome Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-06-22","conditions":"Ocular Rosacea, Antimicrobial Resistance","enrollment":50},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT06887192","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis","status":"RECRUITING","sponsor":"MapLight Therapeutics","startDate":"2025-08-15","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":300},{"nctId":"NCT06971731","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-20","conditions":"Phenylketonuria","enrollment":120},{"nctId":"NCT07454408","phase":"PHASE1, PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":"Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS","enrollment":40},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT07226440","phase":"PHASE1, PHASE2","title":"Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-01","conditions":"Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals","enrollment":40},{"nctId":"NCT03586284","phase":"PHASE2, PHASE3","title":"Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-03-15","conditions":"Cytomegalovirus Anterior Uveitis","enrollment":51},{"nctId":"NCT04458324","phase":"PHASE2","title":"Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2020-12-22","conditions":"Spinal Cord Injuries","enrollment":70},{"nctId":"NCT07441395","phase":"PHASE2","title":"Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD","status":"RECRUITING","sponsor":"Corvus Pharmaceuticals, Inc.","startDate":"2026-02","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema","enrollment":200},{"nctId":"NCT07013474","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-14","conditions":"COVID-19 Infection","enrollment":300},{"nctId":"NCT05031780","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-02-11","conditions":"Sickle Cell Disease","enrollment":286},{"nctId":"NCT07444892","phase":"PHASE2","title":"Levodopa for Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-04-18","conditions":"Diabetic Retinopathy","enrollment":230},{"nctId":"NCT04770779","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2021-11-30","conditions":"Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia","enrollment":258},{"nctId":"NCT06563895","phase":"PHASE3","title":"Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","status":"RECRUITING","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2025-05-12","conditions":"Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis","enrollment":582},{"nctId":"NCT04884360","phase":"PHASE3","title":"D9319C00001- 1L OC Mono Global RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Ovarian Cancer","enrollment":366},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT04770753","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2021-12-20","conditions":"Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia","enrollment":194},{"nctId":"NCT05144256","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-06-08","conditions":"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","enrollment":49},{"nctId":"NCT03598309","phase":"PHASE2","title":"Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-05","conditions":"Lung Diseases, Lung Cancer, Protection Against","enrollment":19},{"nctId":"NCT05537220","phase":"PHASE3","title":"Oral N-acetylcysteine for Retinitis Pigmentosa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-10-11","conditions":"Retinitis Pigmentosa","enrollment":485},{"nctId":"NCT07036029","phase":"PHASE1","title":"NAL ER IPF Respiratory Function and Safety Study","status":"RECRUITING","sponsor":"Trevi Therapeutics","startDate":"2025-08-21","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":10},{"nctId":"NCT06273540","phase":"PHASE1","title":"Phase1, STP7 Cocaine Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Stalicla SA","startDate":"2024-04-15","conditions":"Cocaine Use Disorder","enrollment":21},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT07157735","phase":"PHASE2","title":"A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-02-02","conditions":"Parkinson Disease","enrollment":36},{"nctId":"NCT06047262","phase":"PHASE2","title":"Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia","status":"RECRUITING","sponsor":"Marc Donath","startDate":"2024-07-09","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT07432529","phase":"PHASE3","title":"Design and Rationale of the COLT Study","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria Locale ASL 6, Livorno","startDate":"2026-06-01","conditions":"Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE)","enrollment":940},{"nctId":"NCT03553875","phase":"PHASE3","title":"Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"Autism, Autism Spectrum Disorder, Nonverbal Learning Disability","enrollment":25},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Squamous Cell, Non-small-cell Lung","enrollment":851},{"nctId":"NCT07421427","phase":"NA","title":"Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-02-21","conditions":"Amantadine, Duloxetine, Pregabalin","enrollment":150},{"nctId":"NCT04966585","phase":"PHASE4","title":"Pilot Study of Posaconazole in Crohn's Disease","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-08-17","conditions":"Crohn Disease, CARD9 S12N Risk Allele","enrollment":10},{"nctId":"NCT07219511","phase":"PHASE1","title":"A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)","status":"RECRUITING","sponsor":"Vasa Therapeutics","startDate":"2025-11-04","conditions":"Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":42},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":"Colorectal Cancer, Metastatic Colon Cancer","enrollment":76},{"nctId":"NCT06611501","phase":"PHASE2","title":"Glycemic Regulation as Endometriosis Adjunct Treatment","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-05-22","conditions":"Pelvic Pain, Endometriosis","enrollment":14},{"nctId":"NCT07412132","phase":"PHASE3","title":"Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-01-09","conditions":"Bipolar Affective Disorder","enrollment":40},{"nctId":"NCT06305806","phase":"PHASE2","title":"RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Covid19, Long Covid-19","enrollment":181},{"nctId":"NCT05900284","phase":"PHASE2","title":"Safety and Feasibility of Metformin for Sepsis Induced AKI","status":"ENROLLING_BY_INVITATION","sponsor":"Hernando Gomez","startDate":"2023-11-08","conditions":"Sepsis, Septic Shock, Acute Kidney Injury","enrollment":80},{"nctId":"NCT07419633","phase":"NA","title":"This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-02-05","conditions":"Muscle, Cognitive Functioning, Geriatric","enrollment":120},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":"Coronary Artery Bypass Graft","enrollment":90},{"nctId":"NCT05759468","phase":"PHASE2","title":"NAD Augmentation in Diabetes Kidney Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-04-13","conditions":"Type2diabetes, Diabetic Kidney Disease","enrollment":140},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":"Obesity, Muscle Loss","enrollment":120},{"nctId":"NCT04227314","phase":"PHASE3","title":"Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2022-04-10","conditions":"Recurrent Aphtous Stomatitis","enrollment":134},{"nctId":"NCT02032823","phase":"PHASE3","title":"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-04-22","conditions":"Breast Cancer","enrollment":1836},{"nctId":"NCT06736574","phase":"PHASE3","title":"Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-12-19","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":1800},{"nctId":"NCT05223868","phase":"PHASE2","title":"A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-02-03","conditions":"Plaque Psoriasis","enrollment":255},{"nctId":"NCT06685809","phase":"PHASE1","title":"A Phase 1 Study of FZ008-145 in Healthy Subjects.","status":"RECRUITING","sponsor":"Guangzhou Fermion Technology Co., LTD","startDate":"2024-11-25","conditions":"Healthy","enrollment":190},{"nctId":"NCT06024421","phase":"PHASE1","title":"Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2024-05-14","conditions":"Infectious Disease, Pharmacology","enrollment":39},{"nctId":"NCT06972264","phase":"PHASE3","title":"Safety and Efficacy of VDPHL01 in Males With AGA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2025-03-11","conditions":"Androgenetic Alopecia, AGA, Male Pattern Baldness","enrollment":480},{"nctId":"NCT06396858","phase":"PHASE4","title":"Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-07","conditions":"Ischemic Stroke","enrollment":4500},{"nctId":"NCT04104321","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)","status":"SUSPENDED","sponsor":"Galmed Research and Development, Ltd.","startDate":"2019-09-23","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":157},{"nctId":"NCT06215859","phase":"PHASE3","title":"Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy","status":"COMPLETED","sponsor":"Viatris Specialty LLC","startDate":"2023-12-29","conditions":"Acute Pain, Post Operative Pain, Pain","enrollment":579},{"nctId":"NCT02162849","phase":"PHASE4","title":"Reward Sensitivity and Pharmacotherapy for Smoking Cessation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12-14","conditions":"Tobacco Use Cessation","enrollment":204},{"nctId":"NCT07023614","phase":"PHASE2","title":"A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy","status":"RECRUITING","sponsor":"Imbria Pharmaceuticals, Inc.","startDate":"2025-10-06","conditions":"Non-obstructive Hypertrophic Cardiomyopathy","enrollment":165},{"nctId":"NCT02271919","phase":"PHASE4","title":"Varenicline and Combined NRT for Smoking Cessation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-14","conditions":"Cigarette Smoker, Tobacco Use Disorder","enrollment":631},{"nctId":"NCT06481150","phase":"PHASE4","title":"A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Hyperoxaluria","enrollment":18},{"nctId":"NCT06961019","phase":"NA","title":"Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets in Type-2 Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"NovoBliss Research Pvt Ltd","startDate":"2025-08-25","conditions":"Type2 Diabetes Mellitus","enrollment":14},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT06408298","phase":"EARLY_PHASE1","title":"HCQ in Resectable Localized Prostate Cancer","status":"RECRUITING","sponsor":"Lionel.D.Lewis, MD","startDate":"2026-01-06","conditions":"Resectable Localized Prostate Cancer","enrollment":20},{"nctId":"NCT06195072","phase":"PHASE2","title":"Platform Clinical Study for Conquering Scleroderma","status":"RECRUITING","sponsor":"Scleroderma Research Foundation, Inc.","startDate":"2024-04-15","conditions":"Interstitial Lung Disease Due to Systemic Disease, Scleroderma","enrollment":400},{"nctId":"NCT07128199","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2025-12-22","conditions":"NSCLC, Stage IB-IIIA, Lung Cancer, Adjuvant","enrollment":360},{"nctId":"NCT06310967","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease","status":"RECRUITING","sponsor":"Intelligem Therapeutics Australia Pty Ltd.","startDate":"2024-11-12","conditions":"Hyperuricemia, Hypouricemia, Renal","enrollment":60},{"nctId":"NCT07381803","phase":"PHASE3","title":"The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Zhejiang University","enrollment":2804},{"nctId":"NCT03341078","phase":"PHASE2","title":"Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-05-01","conditions":"Methamphetamine-dependence","enrollment":176},{"nctId":"NCT07142291","phase":"PHASE2","title":"PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS","status":"RECRUITING","sponsor":"PhenoNet, Inc.","startDate":"2025-11-25","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":105},{"nctId":"NCT07357727","phase":"PHASE3","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-15","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)","enrollment":460}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Tablet: BID","genericName":"Placebo Tablet: BID","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A Placebo Tablet taken BID (twice a day) is used as a control intervention in clinical trials to compare the effects of other treatments. The Placebo Tablet is a small molecule, as classified by ChEMBL, and has been used in studies for various conditions including COVID-19 Pneumonia, Irritable Bowel Syndrome, and Atrial Fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}